Phase I/Ib Clinical Evaluation of PM54 in Patients with Advanced Solid Tumors

The primary objective of this Phase I/Ib clinical trial is to evaluate the safety and tolerability of **PM54** in patients with **advanced solid tumors**. This is clinically relevant as it aims to determine the appropriate dosage and identify any potential adverse effects, which are critical steps in the development of new therapeutic options for this patient population.

The clinical trial involves a total of **25 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of PM54 in patients with **advanced solid tumors**. This study is structured as a Phase I/Ib trial, which typically involves a small cohort of participants to assess the investigational product's safety profile and determine the appropriate dosage. The trial employs a randomized, double-blind, and controlled design to ensure unbiased results and maintain the integrity of the data collected. The estimated duration of the trial spans from the recruitment start date on April 28, 2023, to the anticipated end date on March 30, 2026.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial is contingent upon the individual's response to the treatment and the occurrence of any adverse events. Participants may be withdrawn from the study early if they experience significant adverse reactions, fail to comply with the study protocol, or choose to withdraw consent. The trial's design and procedures are meticulously planned to ensure the safety and well-being of the participants while providing valuable insights into the potential therapeutic benefits of PM54 for advanced solid tumors.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to commence recruitment on April 28, 2023, with an estimated completion date of March 30, 2026. The trial is categorized under phase 7, indicating a specific stage in the clinical research process. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's impact on the targeted medical condition. The methodology for efficacy assessment will adhere to standard clinical trial protocols, ensuring rigorous and objective evaluation of outcomes. The trial's design will incorporate appropriate tools and instruments to measure efficacy, although these are not specified in the available data.